2月27日 - ** 总部位于马里兰州的疫苗生产商 Novavax NVAX.O 股价盘前上涨 1.6%，报 7.44 美元
** 该公司公布 (link) 第四季度每股亏损 51 美分，去年同期 每股 亏损 1.44 美元，原因是该公司减少了 COVID 疫苗（其唯一上市产品）的支出。
** 该公司于 5 月份与法国制药商赛诺菲SASY.PA签署了 (link) 一份价值至少 12 亿美元的许可协议，将其疫苗在包括美国和欧洲在内的多个市场的销售权移交给了赛诺菲SASY.PA。
** NVAX公司公布的季度销售额为8830万美元，超过了分析师平均 预期的8440万美元--数据由LSEG汇编。
** COVID 疫苗的季度销售额为 4,980 万美元，同比下降 80.2
** NVAX 在过去 12 个月中上涨了 33
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.